Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):116–119. doi: 10.1097/QAI.0b013e31825da73f

Table 1.

Participant characteristics*

Couples with HIV-1 uninfected men Couples with HIV-1 uninfected women

HIV-1 uninfected men HIV-1 infected women HIV-1 uninfected women HIV-1 infected men

Eligible to participate 379 377 112 111
Enrolled prior to July 2011 (N, % of eligible)** 285 (75.2%) 312 (82.8%) 82 (73.2%) 93 (83.8%)
Months since enrollment in Partners PrEP Study (median, IQR) 21 (15 – 27) 21 (15 – 27) 21 (12 – 24) 21 (15 – 27)
Still a couple with study partner (N, %) 243 (85.3%) 253 (82.1%) 67 (81.7%) 72 (80.0%)
Age, years (median, IQR) 34.5 (29.8 – 40.8) : 29.5 (25.1 – 34.4) 33.0 (27.1 – 39.8) 38.2 (34.2 – 44.6)
Children with study partner (median, IQR) 2 (0 – 3) 2 (0 – 3)
Partnership duration, years (median, IQR) 4.4 (1.8 – 9.9) 10.0 (4.2 – 19.7)
On ART at the time of data collection (N, %) 59 (18.9) 24 (25.8)
Not on ART and not eligible for ART*** (N, %) 203 (65.1) 54 (58.1)
*

Couples were offered enrollment separately – 323 couples (250 with HIV-1 uninfected men and 73 with HIV-1 uninfected women) had participation from both members.

**

Data analysis included only couples who enrolled prior to the placebo arm discontinuation of the Partners PrEP Study in July 2011.

***

Under current Kenyan ART guidelines.

HHS Vulnerability Disclosure